Epygenix Therapeutics, Inc.

We are a clinical stage precision medicine-based biopharmaceutical company developing drugs for rare and intractable forms of genetic epilepsy.

We aim to be a leader in the rare genetic epilepsy space with our diversified drug pipeline.

We will be the first biopharmaceutical company to launch novel epilepsy drugs discovered in zebrafish-based screening system.

Epygenix Therapeutics is currently engaged in pivotal clinical studies for Dravet syndrome and Lennox-Gastaut syndrome. Our goal is to develop safe and effective treatment for these intractable epilepsies.


Argus Trial

Epygenix is currently running a single privatol study for Dravet syndrome patients with EPX-100.


Therapeutic Focus

Epygenix Therapeutics focuses on development of new treatments for rare and catastrophic forms of genetic epilepsy, including Dravet Syndrome, Lennox-Gastaut Syndrome, Ohtahara Syndrome, and other rare genetic epilepsies.



Our technology is based on pioneering zebrafish epilepsy models and drug screening developed at the University of California, San Francisco. This unique approach combines first-in-class modeling of genetic epilepsies with high-throughput phenotype-based drug screening.

What is Epygenix?

Epygenix Therapeutics is a clinical stage biopharmaceutical company developing drugs to treat Dravet syndrome (DS) and other genetic epilepsies. DS is a rare and catastrophic form of intractable epilepsy that begins in infancy. Current therapeutic options are not sufficient, and the constant care required can severely impact the quality of life for the entire family.

Recent News and Press Releases

Jul 21, 2022

Epygenix Therapeutics to Participate in RW Baird’s Biotech Discovery Series

Jun 29, 2022

Epygenix Therapeutics Receives FDA Orphan Drug Designation for EPX-100 For Treatment of Ohtahara Syndrome

Jun 09, 2022

Epygenix Therapeutics to Provide Update at the Dravet Syndrome Foundation (DSF) 2022 Conference

Jun 01, 2022

First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome

May 23, 2022

Epygenix Therapeutics Announces Appointment of Dr. Lorianne Masuoka as Chief Medical Officer

May 20, 2022

Epygenix Therapeutics To Participate in UBS Healthcare Virtual 1×1 Day

Mar 23, 2022

Epygenix Therapeutics Announces Appointment of G. Michael Landis as Chief Financial Officer

Mar 15, 2022

Epygenix Therapeutics Announces Appointment of Darren Cline as CEO

Feb 16, 2022

Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome

Aug 30, 2021

Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome

Aug 02, 2021

Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome

Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome

Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome

May 03, 2021

Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies

Sep 17, 2020

Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100

Sep 16, 2020

EpyGenix Launches Phase II Trial for EPX-100

Jan 27, 2020

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

Jul 29, 2019

Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome

Jun 24, 2019

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

Jun 26, 2017

A New School of Drug Discovery

Apr 25, 2017

Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome

Feb 10, 2017

Epilepsy drug discovered in fish model shows promise in small pediatric clinical trial

Jan 18, 2017

Through the Looking Glass: The Quest by Parents and Scientists to End Pediatric Epilepsy

Jan 17, 2017

Potential Drug Discovered for Severe Form of Epilepsy

To Learn More